Document is current
Any future updates will be listed below
-
Authors
Kudling, Tatiana V. https://orcid.org/0000-0003-4481-1617
Bychkov, Dmitrii
Clubb, James H. A.
Pakola, Santeri A. https://orcid.org/0000-0001-6235-8612
Arias, Victor
Jirovec, Elise https://orcid.org/0009-0004-0606-6577
van der Heijden, Mirte
Ojala, Nea
Quixabeira, Dafne C. A.
Haybout, Lyna https://orcid.org/0009-0005-5170-5611
Jalkanen, Katriina J.
Alanko, Tuomo
Havunen, Riikka https://orcid.org/0009-0008-7926-5285
Sorsa, Suvi
Kistler, Claudia
Kanerva, Anna
Hemminki, Otto
Santos, Joao M.
Cervera-Carrascon, Victor
Hemminki, Akseli https://orcid.org/0000-0001-7103-8530
- License Information
-
More Information
Article History
Received: 27 November 2024
Revised: 10 March 2025
Accepted: 28 March 2025
First Online: 10 April 2025
Competing interests
: JHAC, CK, JMS and VC-C are employees and shareholders of TILT Biotherapeutics Ltd. DCAQ, LH, SS and RH are employees of TILT Biotherapeutics Ltd. AH is an employee and shareholder in TILT Biotherapeutics Ltd and shareholder in Circio Holdings ASA. All other authors declare no competing interests.
: The TUNIMO trial protocol and ethics were reviewed by the Finnish Medical Agency and the Helsinki University Hospital Ethics board (approval 49/2020 and statement HUS/1804/2020). All patients gave written informed consent for participation. All study procedures were conducted in accordance with the relevant guidelines and regulations.
: All patients gave written informed consent for publication of their clinical information.
